1 The EIC Accelerator Project
EIC Accelerator Program: An Overview
The EIC Accelerator program, part of the European Innovation Council (EIC), is designed to support startups and small to medium-sized enterprises (SMEs) with innovative ideas that have the potential to scale up and significantly impact the market. The program offers a unique blend of grant funding and equity investments, making it a vital resource for companies in the European DeepTech and startup ecosystem.
Funding Structure
The EIC Accelerator provides two primary forms of funding: grants and equity.
Purpose in the Ecosystem
The primary purpose of the EIC Accelerator is to nurture innovation by providing essential support to early-stage companies. It aims to bridge the funding gap that often exists for startups, particularly in the DeepTech sector, which requires significant investment in research and development. By enabling companies to scale, the EIC Accelerator plays a crucial role in fostering economic growth, job creation, and technological advancement across Europe.
Role in Scaling Companies
The EIC Accelerator aids companies in scaling by offering not only financial resources but also strategic support. This includes access to a network of investors, business mentors, and industry experts. The program encourages collaboration and knowledge sharing among startups, thereby enhancing their chances of success in a competitive market. By facilitating connections with private sector players, the EIC Accelerator helps companies secure additional funding, which is often critical for growth and market penetration.
JAXBIO TECHNOLOGIES LTD and the LUMEN Project
One of the notable winners of the EIC Accelerator is JAXBIO TECHNOLOGIES LTD, which secured funding for its project titled LUMEN. This project focuses on an innovative liquid biopsy method using lab-on-a-chip technology for cancer diagnosis and management.
Project Overview: LUMEN
The LUMEN project aims to revolutionize cancer diagnostics through a cutting-edge liquid biopsy method. Liquid biopsies are non-invasive tests that analyze biomarkers in bodily fluids, such as blood, to provide insights into cancer presence and progression. The lab-on-a-chip technology embedded in the LUMEN project allows for the rapid and accurate detection of cancer biomarkers, streamlining the diagnostic process.
Technology Background
Liquid biopsies represent a significant advancement over traditional tissue biopsies, which are often invasive and pose various risks to patients. The lab-on-a-chip technology employed by JAXBIO integrates multiple laboratory functions onto a single chip, enabling the analysis of minute quantities of biological samples. This technology utilizes microfluidics to manipulate small volumes of fluids, allowing for high-throughput screening and real-time monitoring of cancer biomarkers.
The LUMEN project leverages proprietary algorithms and machine learning to enhance the accuracy of cancer detection, making it possible to identify cancer at earlier stages. This early detection is critical for improving treatment outcomes and patient survival rates.
Conclusion
The EIC Accelerator program serves as a fundamental pillar in supporting innovative startups like JAXBIO TECHNOLOGIES LTD. By providing a combination of grant funding and equity investments, the program enables companies to develop groundbreaking solutions, such as the LUMEN project. As the landscape of cancer diagnostics continues to evolve, initiatives like the EIC Accelerator will play a vital role in fostering innovation, enhancing healthcare, and ultimately improving patient outcomes across Europe and beyond.
2 The Funding Rounds
JAXBIO TECHNOLOGIES LTD: Funding and Financing Overview Since EIC Accelerator Award
JAXBIO Technologies Ltd, headquartered in Netanya, Israel, is an innovative biotech company specializing in blood-based diagnostics for early cancer detection and monitoring. Since being awarded funding from the EIC Accelerator programme on March 13, 2024, the company has experienced a series of financing milestones across grants and equity investments.
Financing Raised
- Total Funding: Estimates of total capital raised by JAXBIO Technologies vary by source:
- CB Insights reports a total raise of $15.16 million.
- Startup Nation Central lists $11.98 million.
- Invenia Group details a notable grant round totaling approximately $2.78 million around July 2024.
- EIC Accelerator Grant & Equity: The European Innovation Council (EIC) Accelerator award typically includes up to €2.5 million in non-dilutive grant funding plus up to €15 million in equity investment per company. JAXBIO Technologies was one of nine Israeli startups to receive this support as part of an aggregate €108 million awarded to Israeli companies through the programme.
Funding Rounds: Timing and Amounts
The company's funding history since its EIC Accelerator win includes:
| Date | Type | Amount | Notes |
|---|---|---|---|
| ~July 2024 | Grant | ~$2.78M USD | Major grant round reported |
| ~August 2024 | Grant/Grant III | Unspecified (estimates suggest additional millions) | CB Insights notes latest round as "Grant III" as of August 19, 2024 |
| Ongoing | Multiple (since founding) | Up to ~$17.66M USD cumulative | Total sums vary across sources; includes all grants/equity |
*CB Insights references both "Grant II" ($9M raised about one year prior) and "Grant III," suggesting staged or milestone-driven financing through public innovation funds or accelerator tranches.
Investor Information
Key investors supporting JAXBIO Technologies include:
- Horizon Europe
- European Research Council
- Ramot at Tel Aviv University
These are predominantly public or institutional investors focused on deep-tech research commercialization rather than traditional venture capital funds.
Company Valuation
No explicit market capitalization or post-money valuation figures for JAXBIO Technologies have been publicly disclosed as of May 2025. This is common for startups still at early growth stages or those receiving primarily non-dilutive public funding.
Exit Events: IPOs, Buyouts, Acquisitions
There are no records indicating that JAXBIO Technologies has undergone any exit events such as an initial public offering (IPO), acquisition, buyout, or merger since securing its EIC Accelerator award through May 2025.
Summary Table: Recent Key Financial Data
| Parameter | Value/Status |
|---|---|
| Total Funding Raised | $11.98–$17.66M USD (varies by source) |
| Largest Single Round | ~$2.78M grant (~July/August 2024) |
| Principal Investors | Horizon Europe; ERC; Ramot TAU |
| Most Recent Valuation | Undisclosed |
| Exit Events | None reported |
Sources
- JaxBio Technologies - CB Insights
- JaxBio Technologies - Startup Nation Finder
- Biotech funding roundup for July - Invenia Group
- €108 Million Awarded to Israeli Startups by European Innovation Council’s EIC Accelerator Programme
3 The Press Releases
JaxBio Technologies: EIC Accelerator Grant and Liquid Biopsy Advancements JaxBio Technologies, an Israeli medical diagnostics company based in Netanya, secured a €2.5 million grant from the European Innovation Council (EIC) Accelerator in March 2024. The funding includes potential blended financing of up to €18.2 million, combining EU grants and matched investor contributions.Key Developments
- Technology: JaxBio’s LUMEN liquid biopsy platform uses lab-on-a-chip technology and AI algorithms to detect epigenetic signatures in cell-free DNA, enabling early cancer diagnosis (particularly lung cancer) with high sensitivity at low cost. The method eliminates DNA sequencing requirements, delivering next-day results for clinical decision-making.
- Clinical Focus: The funds will advance clinical trials for LUMEN, aiming to create a companion diagnostic tool for predicting therapy response and monitoring tumor recurrence. The technology also has potential applications in heart disease and neurological disorders.
- Leadership: Founded and led by CEO Dr. Shahar Zirkin, JaxBio emphasizes rapid diagnostics to address late-stage cancer diagnoses globally.
Strategic Context
The EIC grant follows JaxBio’s earlier participation in the EU Horizon Europe Cancer Mission’s SANGUINE study, developing array-based diagnostics for hematological malignancies coordinated by Tel Aviv University. No recent press releases from jaxbio.com were found in available sources, but third-party announcements highlight their focus on scaling clinical validation efforts post-funding.Sources
- JaxBio Technologies Secures €2.5M Grant from European Innovation Council
- Medical Diagnostics Company JaxBio Secures €2.5M Grant
4 The Technology Advancements
JAXBIO Technologies Ltd: Current Capabilities and Advancements
JaxBio Technologies Ltd, an Israeli company, has been at the forefront of developing innovative liquid biopsy methods using lab-on-a-chip technology for cancer diagnosis and management. Their platform is designed to detect thousands of cancer-specific biomarkers circulating in the blood at high sensitivity and low cost, utilizing machine learning algorithms to identify different types and subtypes of cancer.
Current Capabilities
- Early Cancer Diagnosis: JaxBio aims to revolutionize cancer diagnosis with a simple and sensitive blood test, enabling early detection, monitoring of disease status, and predicting response to therapy.
- Technology: Their unique platform combines advanced biomarker analysis with machine learning to enhance cancer detection capabilities.
Advancements Since EIC Accelerator Funding
As of the March 2024 funding date, specific details about new advancements or improvements in technology by JAXBIO Technologies Ltd are not publicly documented. However, the company received significant recognition and funding, including a Horizon Europe Cancer Mission Grant for a project named SANGUINE, which was awarded approximately €8.5 million.
Technology Demonstration and Development
There is no publicly available information indicating that JAXBIO Technologies Ltd has conducted market demonstrations, customer trials, or clinical trials specifically since receiving the EIC Accelerator funding in March 2024. Their focus remains on developing and refining their diagnostic platform for widespread use in cancer management.
Patents, Scientific Studies, and Clinical Trials
No recent publications or filings related to new patents, scientific studies, or clinical trials by JAXBIO Technologies Ltd have been reported since their funding in March 2024.
Conclusion
While JAXBIO Technologies Ltd continues to innovate in the field of cancer diagnostics, specific advancements or new features post-EIC funding are not detailed in available sources. Their commitment to improving cancer diagnosis through advanced technology remains a core focus.
Sources
- JaxBio: Home
- Startup Nation Finder: JaxBio Technologies
- News - JaxBio
- Alien Technology Transfer: JAXBIO TECHNOLOGIES LTD
5 The Partnerships and Customers
JaxBio Technologies Ltd: Strategic Positioning and Partnerships Post-EIC Accelerator Funding Since securing EIC Accelerator funding in March 2024, JaxBio Technologies Ltd has focused on advancing its proprietary blood-based cancer diagnostic platform, which leverages AI-driven biomarker analysis for early cancer detection. While specific customer names remain undisclosed in available records, the company’s public-facing materials emphasize its commitment to transforming oncology diagnostics through scalable, cost-effective solutions.Partnerships and Market Positioning
As of early 2025, JaxBio is not explicitly named in recent partnership announcements within the provided data. However, broader industry trends highlight increased collaboration between diagnostic developers and therapeutic companies to advance companion diagnostics (CDx), a space where JaxBio’s technology could align. For example, competitors like Burning Rock and Bayer have partnered on next-generation sequencing (NGS)-based CDx development, indicating a market shift toward integrated diagnostic-therapeutic ecosystems that JaxBio may leverage.
The company’s focus on AI-driven biomarker panels positions it to address unmet needs in precision oncology by enabling earlier intervention and therapy monitoring. If JaxBio engages in partnerships akin to PathAI-Roche’s AI-enabled CDx collaboration or Guardant Health’s Medicare-covered liquid biopsy tests, it could accelerate regulatory approvals and commercialization.
Technology Advancements and Scaling Pathways
JaxBio’s proprietary platform combines high-sensitivity biomarker detection with machine learning algorithms to identify cancer-specific patterns across thousands of analytes. This approach is inherently scalable for pan-cancer screening applications. Potential collaborations with pharmaceutical companies or CROs (e.g., similar to ARUP-Medicover’s EU CDx expansion) could facilitate:
- Clinical validation studies, particularly for rare cancers or minimal residual disease monitoring.
- Regulatory strategy optimization, using precedents from FDA-approved CDx assays like Agilent-Qiagen products.
- Manufacturing scalability, through partnerships with liquid biopsy workflow specialists such as Guardant Health or Thermo Fisher Scientific.
While direct customer traction remains unreported, the EIC Accelerator funding likely supports pilot deployments with academic medical centers or biopharma partners pursuing co-development opportunities. Future alliances may follow models like AstraZeneca-Almac’s CDx pact or MeiraGTx-Hologen Neuro AI’s gene therapy joint venture, focusing on therapeutic alignment across high-value oncology indications.
Sources
- JaxBio Technologies - Startup Nation Finder
- JaxBio: Home
- Global Companion Diagnostic Market Research 2025
6 The Hiring and Company Growth
JaxBio Technologies: Team Growth and Development Post-EIC Accelerator Funding JaxBio Technologies, an Israeli biotech firm specializing in blood-based cancer diagnostics, has positioned itself as a leader in early cancer detection through its proprietary biomarker analysis and AI-driven diagnostic platform. While specific details about recent hiring activity or current headcount are not publicly disclosed, insights into their team structure and strategic direction can be derived from available information.Team Composition and Expertise
The company emphasizes a cross-disciplinary approach, with teams spanning cancer biology, genomics, chemistry, bioinformatics, and machine learning. This diversity reflects their focus on integrating advanced diagnostic technologies with AI to improve cancer detection accuracy.Scaling Efforts Post-Funding
As an EIC Accelerator winner (March 2024), JaxBio is likely leveraging funding to expand its operational capacity. Although exact growth metrics are unavailable, typical scaling for such firms involves:- R&D expansion: Enhancing biomarker discovery and AI algorithm training.
- Talent acquisition: Recruiting specialists in computational biology or clinical validation to accelerate product development.
Hiring Priorities and Strategic Roles
While no recent hires are explicitly listed, the company’s mission suggests ongoing recruitment for roles critical to:- Clinical trials management: For upcoming test validation phases.
- Regulatory affairs: To navigate approvals for diagnostic devices globally.
- AI/ML engineering: To refine predictive models for cancer subtype classification.
Leadership Stability
No changes in founding team composition have been reported; the leadership appears focused on advancing their core technology toward commercialization. New hires would likely reinforce existing departments rather than signify management restructuring.Sources
JaxBio Technologies - Startup Nation Finder | JaxBio Official Website | About JaxBio
7 The Media Features and Publications
JaxBio Technologies Ltd. Overview
JaxBio Technologies Ltd., based in Israel, has gained significant recognition for its innovative approach to cancer diagnosis and management. The company focuses on developing a simple and sensitive blood test for early cancer detection, utilizing advanced technologies to identify cancer-specific biomarkers. This approach aims to enhance cancer treatment efficacy by enabling early detection and monitoring of disease progression.
Media Features and Publications
JaxBio Technologies has been featured in various news outlets due to its innovative work in cancer diagnostics. The company's involvement in the European Union's Horizon program has been highlighted, where it received significant funding. Additionally, JaxBio was mentioned in the context of the companion diagnostics market, noting its plans to create array-based cancer tests.
Content from Publications
Publications have emphasized JaxBio's mission to revolutionize cancer diagnosis through its blood test technology. The test is designed to be fast, affordable, and highly sensitive, leveraging machine learning to identify biomarkers for different cancer types and stages. The company's ability to probe thousands of cancer-specific biomarkers in blood samples has been highlighted as a key advantage.
Podcasts or Interviews
Currently, there is no specific information available about podcasts or interviews featuring the team from JaxBio Technologies.
Conference and Fair Participations
There is no detailed information on specific conferences or fairs that JaxBio Technologies has participated in. However, the company's involvement in the broader context of biomedical innovation suggests potential participation in relevant industry events.
Event Involvement
JaxBio Technologies received funding from the European Innovation Council (EIC) Accelerator program, which includes grants and equity investments to support its growth. This funding is part of a broader initiative to accelerate innovation in the European Union.
EIC Accelerator Funding
On March 13, 2024, JaxBio Technologies successfully secured funding through the EIC Accelerator program, marking a significant milestone in its development. The company had previously received a €2.5 million grant from the EIC Accelerator, emphasizing the EU's support for innovative startups like JaxBio.
Sources
- News - JaxBio
- JaxBio: Home
- JaxBio Technologies - Startup Nation Finder
- Global and US Companion Diagnostic Market Research 2025
- Nine Israeli startups secure $142 million in funding from EU Horizon
- Alien Technology Transfer
Do you need EIC Accelerator support?
Here is a list of the key service options for the EIC Accelerator:
Full Writing Service
All proposal sections are written by Stephan Segler, PhD.
Advisory Service
You write in-house but receive 1-on-1 support, templates, instructions, and reviews of all documents.
AI Writer & Training
A high-quality AI writer for EIC Accelerator Step 1 and a comprehensive Training program for Steps 1 and 2 including all templates and instructions.